Bessemer Group Inc. Acquires 5,028,603 Shares of Pfizer Inc. $PFE

Bessemer Group Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3,684.3% during the first quarter, Holdings Channel.com reports. The firm owned 5,165,091 shares of the biopharmaceutical company’s stock after acquiring an additional 5,028,603 shares during the quarter. Bessemer Group Inc.’s holdings in Pfizer were worth $145,037,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank raised its position in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. raised its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its stake in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding use of the combination as a new treatment option and supporting the company’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analyst commentary remains constructive on Pfizer’s valuation, with some recent coverage suggesting the stock may still offer upside versus Wall Street targets despite recent weakness. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Neutral Sentiment: Market commentary also says Pfizer’s shares are below key moving averages, reflecting a cautious technical setup as investors weigh fading COVID revenue against pipeline growth, acquisitions, and dividend support. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Pfizer also faces a new patent dispute, as Arbutus Biopharma filed international lawsuits over lipid nanoparticle technology used in mRNA COVID-19 vaccines. The case adds legal overhang, though the financial impact is still uncertain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India due to supply challenges, which could weigh on near-term international product sales and signals execution issues in the supply chain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer Stock Performance

NYSE:PFE opened at $25.13 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a fifty day moving average of $25.22 and a 200-day moving average of $26.18. The firm has a market capitalization of $143.24 billion, a P/E ratio of 19.19 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. BMO Capital Markets decreased their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.